Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Genzyme gets rights to Osiris's Prochymal and Chondrogen; deal terminated

Executive Summary

In a deal potentially worth $1.38bn in up-fronts and total milestones, Genzyme received exclusive rights to develop and commercialize stem cell company Osiris Therapeutics' Prochymal and Chondrogen adult stem cell products worldwide, with the exception of the US and Canada, where Osiris retains rights; and in Japan, where Prochymal was previously licensed in the graft-versus-host disease (GvHD) indication.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • Intra-Biotech Deal
    • R&D and Marketing (Licensing)

Related Companies